Relay Therapeutics, Inc. RLAY Other Commercial Liabilities
Other Commercial Liabilities at other companies
Other financials
Where this comes from
Reported directly by Relay Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AccruedLiabilitiesCurrent.
The official record: Relay Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Relay Therapeutics, Inc.'s other commercial liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Relay Therapeutics, Inc.'s other commercial liabilities?
- Relay Therapeutics, Inc. (RLAY) reported other commercial liabilities of $20.91M in Q1 2026.
- How has Relay Therapeutics, Inc.'s other commercial liabilities changed year-over-year?
- Relay Therapeutics, Inc.'s other commercial liabilities decreased by 0.4% year-over-year, from $20.99M to $20.91M.
- What is the long-term trend for Relay Therapeutics, Inc.'s other commercial liabilities?
- Over 5 years (2020 to 2025), Relay Therapeutics, Inc.'s other commercial liabilities has grown at a 18.8% compound annual growth rate (CAGR), from $5.76M to $13.65M.